Overview

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Status:
Withdrawn

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

Safety run-in (part 1): Relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL) Main study (part 2): Relapsed or refractory diffuse large B-cell lymphoma

Phase:

Phase 1

Details

Lead Sponsor:

Royal Marsden NHS Foundation Trust

Collaborators:

Merck Sharp & Dohme Corp.
Mundipharma-EDO GmbH

Treatments:

Pembrolizumab
Rituximab